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Background: Medulloblastoma is the most common type of malignant brain tumor that afflicts children. Although
recent advances in chemotherapy and radiation have improved outcomes, high-risk patients do poorly with
significant morbidity.
Methods: To identify new molecular targets, we performed an integrated genomic analysis using structural and
functional methods. Gene expression profiling in 16 medulloblastoma patient samples and subsequent gene set
enrichment analysis indicated that cell cycle-related kinases were associated with disease development. In addition
a kinome-wide small interfering RNA (siRNA) screen was performed to identify kinases that, when inhibited, could
prevent cell proliferation. The two genome-scale analyses were combined to identify key vulnerabilities in
medulloblastoma. The inhibition of one of the identified targets was further investigated using RNAi and a small
molecule inhibitor.
Results: Combining the two analyses revealed that mitosis-related kinases were critical determinants of
medulloblastoma cell proliferation. RNA interference (RNAi)-mediated knockdown of WEE1 kinase and other mitotic
kinases was sufficient to reduce medulloblastoma cell proliferation. These data prompted us to examine the effects
of inhibiting WEE1 by RNAi and by a small molecule inhibitor of WEE1, MK-1775, in medulloblastoma cell lines.
MK-1775 inhibited the growth of medulloblastoma cell lines, induced apoptosis and increased DNA damage at
nanomolar concentrations. Further, MK-1775 was synergistic with cisplatin in reducing medulloblastoma cell
proliferation and resulted in an associated increase in cell death. In vivo MK-1775 suppressed medulloblastoma
tumor growth as a single agent.
Conclusions: Taken together, these findings highlight mitotic kinases and, in particular, WEE1 as a rational
therapeutic target for medulloblastoma.
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Medulloblastoma is the most common malignant brain
tumor in children. Over 800 cases per year occur world-
wide with the vast majority occurring in children less
than 12 years of age [1]. The mainstays of medulloblas-
toma therapy continue to be surgery, radiation and cyto-
toxic chemotherapy [2]. While therapy for standard risk
patients has resulted in improved outcomes, high-risk
patients do poorly. In particular those showing relapse
and MYC amplification have a 5-year survival rate of less
than 40% [3]. In addition, there remains significant
therapy-related morbidity, particularly in the very young
patients [4-6]. Novel therapeutic approaches based on
tumor biology are clearly needed to improve outcomes
for these children.
Recent genomic analysis has been successfully used to
identify medulloblastoma subtypes [7-10]. International
consensus has resulted in four molecular subgroups be-
ing defined [11]. These are the Wnt and Shh signaling
subgroups as well as Group 3 and 4. Group 3 tumors
largely represent the MYC amplified tumors whereas
there is not a clear molecular definition of the Group 4
tumors [11]. However, finding therapeutic targets from
these categories is still challenging [12]. Patients with
the Wnt signaling signature are in a very good risk cat-
egory and efforts are underway to de-escalate therapy
for this cohort of patients [13]. For patients with the Shh
signature, there are targeted inhibitors currently in early
phase trials [13]. Unfortunately molecular targeting for
Group 3 and 4 tumors is less clear. This is particularly
problematic since Group 3 and 4 tumors constitute 60%
of all medulloblastoma tumors [11].
The advent of RNA interference (RNAi) technologies
for targeting large sets of genes in mammalian cells al-
lows us to systematically interrogate gene functions in a
high throughput manner [14,15]. This functional gen-
omic approach has successfully resulted in the discovery
of genes that were components of Ras oncogene driven
tumors [16,17], of genes that sensitize cells to chemo-
therapeutic agents [18], and of genes essential to the
proliferation of such diverse cancer cells as neuroblast-
oma and renal cell carcinoma [19,20].
Here we use an integrated descriptive and functional
genomic analysis to identify molecular targets for medul-
loblastoma therapy. We performed pathway and gene set
enrichment analysis on expression profiling data from 16
medulloblastoma samples to identify potential targetable
pathways. In conjunction we performed a kinome-wide
siRNA screen of medulloblastoma cells. Combined these
results identified a set of mitotic-related kinases as poten-
tial therapeutic targets for medulloblastoma. We show
that genetic and chemical inhibition of one of these ki-
nases, WEE1, potently suppresses cell growth, induces
apoptosis and decreases tumor volume in vivo inmedulloblastoma. Further a small molecule inhibitor,
MK-1775, acts in synergy with cisplatin to induce me-
dulloblastoma cell death in vitro.
Materials and methods
Cell lines and primary patient samples
Dr. Darell D. Bigner (Duke University Medical Center,
NC) kindly provided the D425 and D458 medulloblas-
toma suspension cell lines. The ONS-76 medulloblas-
toma cell line was graciously given by Dr. James T.
Rutka (University of Toronto, Canada) and the UW228
cell line by Dr. John Silber (University of Washington,
Seattle). The Daoy and D283 medulloblastoma cell lines
were purchased from American Type Cell Culture (Rockville,
MD). All cell lines were cultured in DMEM (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA).
The discovery cohort of 16 medulloblastoma patient
samples used for gene expression profiling in Figure 1B
and additional patient samples representing primitive
neuroectodermal tumor, glioblastoma multiforme and
pilocytic astrocytoma were obtained from Children’s
Hospital Colorado and was conducted in accordance
with local and federal human research protection guide-
lines and Institutional Review Board (IRB) regulations.
Informed consent was obtained for all specimens col-
lected. Normal cerebellum collected from autopsy was
purchased from Ambion (Austin, TX), Stratagene (Santa
Clara, CA) and Clontech Laboratories, Inc. (Mountain
View, CA). The other normal cerebellar samples (UPN
514 and UPN 605) were obtained from nonmalignant
brain biopsies at the Children’s Hospital Colorado under
IRB guidelines. UPN 514 and UPN 605 are from 4 year
old and 5 year old patients, respectively. The second
large cohort of 90 tumor specimens were obtained in ac-
cordance with the Research Ethics Board at the Hospital
for Sick Children (Toronto, Canada) and the N. N. Burdenko
Neurosurgical Institute (Moscow, Russia) and data analysis
was performed as described [7]. The second cohort was used
to generate WEE1 gene expression array data for the normal
cerebellum and the four distinct medulloblastoma molecular
subgroups given in Figure 2C.
Transfections with RNAi
The siPORT NeoFX Transfection Agent purchased from
Ambion was used to transfect the siRNAs targeting
WEE1 mRNA (s21) and a non-targeting siRNA into me-
dulloblastoma cell lines at a final concentration of 5 nM.
The manufacturer’s suggested protocol for a reverse
transfection was used with the siRNA.
Small molecule inhibitor of WEE1
The small molecule WEE1 inhibitor, MK-1775, was pur-
chased from Axon Medchem (Groninberg, Netherlands)
Figure 1 Analysis of cell cycle-related kinases in medulloblastoma. (A) Schematic of the integrated genomic analysis undertaken to identify
novel targets in medulloblastoma. This approach identified 50 potential cell cycle-related kinases in medulloblastoma. (B) Heat map showing the
gene expression of the 50 identified dysregulated cell cycle-related kinases in 16 medulloblastoma patient samples compared to three normal
cerebellum samples. (C) Dot plot showing the average Z score for the 710 human kinase genes targeted in the siRNA screen. Each dot represents
the average Z score of the 3 separate siRNAs targeting that single kinase. (D) The table lists the top 12 kinase genes with the lowest Z score from
the siRNA screen performed in Daoy medulloblastoma cells.
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used to reconstitute the drug and subsequent aliquots
were stored in a desiccator at -20°C. An equivalent
amount of DMSO for the highest concentration of drug
was used for each experiment as a vehicle control.
Cell proliferation assays
Cell growth was measured using the xCELLigence system
and E-Plate 96-well gold-coated plates (Roche, Indianapolis,
IN). This system gives the real-time measurement of cellproliferation [21]. Cells were transfected with a siRNA
against WEE1 or with a non-targeting siRNA control for
48 hours. Cells were then trypsinized and 2000 cells were
plated in to a well of an E-plate and cell growth was
measured.
Cell proliferation was determined by MTS [3-(4, 5-
dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] assay using CellTiter
96 AQueous One Solution (Promega, Madison, WI). For
RNAi experiments 20 μL of MTS reagent was added to
Figure 2 Mitotic kinases as therapeutic targets in medulloblastoma. (A) The Venn diagram shows the overlap of 29 kinases identified by
gene expression analysis to have high expression in medulloblastoma with 95 kinases found to be important for medulloblastoma proliferation in
the siRNA kinase screen. WEE1 was one of the 6 kinases in common between the two approaches. (B) Model of G2-M kinases that mediate Daoy
cell proliferation. Kinases in red are the hits from the combination of gene expression analysis and the kinome-wide RNAi screen. (C) WEE1 mRNA
expression in 90 medulloblastoma patient samples shows a significant increase when compared to normal adult cerebellum (Adult CB) by
microarray analysis. There is no significant difference in WEE1 expression between the 4 subgroups of medulloblastoma (Wnt, Shh, Group 3 and
Group 4). (D) Microarray analysis shows an increase in WEE1 mRNA expression in a cohort of pediatric medulloblastoma (Medullo), primitive
neuroectodermal tumors (PNET), glioblastoma multiforme (GBM) and pediatric pilocytic astrocytoma (PA) when compared to normal brain
specimens. (E) WEE1 protein levels are increased in six common medulloblastoma cell lines. UPN 514 and UPN 605 are from normal pediatric
cerebellum lysates (Normal CB).
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transfection. For chemical inhibitor experiments cells were
plated for 24 hours before adding MK-1775. Then
72 hours after the addition of the drug, 30 μL of MTS re-
agent was added to the wells to make a final volume of
180 μL. The optical densities of the triplicate wells wereread using a BioTek Synergy 2 plate reader (Winooski,
VT) every hour for 4 hours after the addition of the MTS
reagent. Background absorbance was subtracted from all
wells before analysis. The half maximal inhibitory concen-
tration (IC50) values for the drug were calculated from
the corrected absorbance values using GraphPad Prism.
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Cells were initially transfected with siRNA and then after
48 hours were counted and replated at 500 cells per well
of a 6-well plate in triplicate. Colony formation assays
utilizing MK-1775 were plated at the same density as
above for 24 hours before drug addition. Wells were
then treated with drug for 24 hours and subsequently
allowed to grow in normal culture medium. Cells were
allowed to grow for seven days, then the medium was
aspirated, the wells were washed with phosphate buff-
ered saline (PBS) and the colonies were stained with
0.5% crystal violet/25% methanol solution. A dissecting
microscope was used to count the number of colonies
per well with a threshold of 50 cells necessary to consti-
tute a colony.
Cell apoptosis assay
Cells were treated for 24 hours with drug and then
allowed to grow in normal culture medium for an add-
itional 24 hours. The cell concentration was determined
following staining with Guava ViaCount reagent (Millipore,
Billerica, MA). Equal numbers of cells were then stained
using Guava Nexin reagent (Millipore) to detect apoptotic
cells. Samples were run on a Guava EasyCyte Plus flow
cytometer (Millipore).
Immunofluorescence
Three thousand cells grown in poly-D-lysine coated
chamber slides were treated with either an IC25 of cis-
platin, an IC30 of the WEE1 inhibitor MK-1775, cis-
platin plus MK-1775 or DMSO for 6 hours or 24 hours.
After treatment cells were washed and fixed with 4%
paraformaldehyde for 15 minutes at room temperature.
Cells were then permeabilized with 0.2% Triton X-100
in PBS for 15 minutes followed by incubation in 5% milk
diluted in 0.05% Triton X-100 for 30 minutes at room
temperature on a shaker. After blocking, cells were incu-
bated with the primary antibodies. The following anti-
bodies were used at a dilution of 1:200: anti-γH2AX
(Ser139), anti-phospho-H3 (Ser10) or anti-caspase 3 for
1 hour at room temperature. After washing with 0.05%
Triton X-100 (3 times for 5 minutes each) cells were in-
cubated with Alexa Fluor 488 conjugated secondary
antibody (1:500) for 1 hour at room temperature in the
dark, washed with PBS (3 times for 5 minutes each) and
mounted using ProLong Gold antifade reagent contain-
ing DAPI (Invitrogen). Images were acquired using an
inverted epifluorescence microscope at a magnification
of 20x. At least three random fields were chosen to
count cells containing greater than 10 foci.
RNAi kinase screen
A siRNA library containing 3 siRNAs per kinase for 710
human kinase genes was purchased from Ambion (catalog#4397918). The siRNAs in the 96-well plates were resus-
pended in nuclease-free sterile water to a concentration of
1 μM. Aliquots of the siRNAs were further diluted into
daughter plates at a concentration of 250 nM. Daoy cells
from the same passage were used to perform the screen.
Briefly, Daoy cells were reverse transfected using siPORT
NeoFX Transfection Agent with a final siRNA concentra-
tion of 5 nM. A separate triplicate set of wells containing
cells transfected with a non-silencing siRNA were in-
cluded on each plate. A MTS assay was performed
72 hours after transfection to determine whether the par-
ticular gene targeted by the siRNA had any effect on cell
proliferation.
Western blotting
RIPA buffer (Thermo Scientific, Rockford, IL) containing
protease inhibitors was used to obtain protein lysates.
Western blotting was performed per standard methods.
Primary antibodies purchased from Cell Signaling Technol-
ogy that were used are WEE1 (#4936), γH2AX (#2577),
phospho-CDK1 (Tyr15) (#4539) and CDK1 (#9112). The
primary antibodies against actin (MAB1501) purchased
from Millipore or β-tubulin (MAB1637) from Chemicon
were used as loading controls. Secondary antibodies con-
jugated to horseradish-peroxidase were used in conjunc-
tion with a chemiluminescent reagent to visualize protein
bands.
Gene expression analysis
Patient tumor samples were evaluated for gene expression
using Affymetrix U133 Plus 2.0 Gene Chip microarrays as
previously described [22]. Briefly, samples were collected
at the time of surgery and snap-frozen in liquid nitrogen.
RNA was extracted from each sample using an RNeasy kit
(Qiagen, Valencia, CA, USA), reverse-transcribed and the
resulting cDNA was converted to cRNA, and hybridized
to HG-U133 Plus 2.0 GeneChips (Affymetrix) according
to the manufacturer’s instructions. Data analysis was per-
formed in R (http://www.r-project.org/) using packages
publicly available through Bioconductor (http://www.bio-
conductor.org). Hierarchical clustering was performed
using the normalized gene expression data. Functional
annotation analysis of differentially expressed genes
was performed with the NIH Database for Annotation,
Visualization, and Integrated Discovery (DAVID) Web
tool (http://david.abcc.ncifcrf.gov/) using Biological Process
Gene Ontology (GO) terms and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways. Gene set enrich-
ment analysis was used to examine enrichment of genes
in predefined reference sets that are based on biological
knowledge [23]. Unlike other approaches that examine
only genes meeting a predetermined cutoff, this tool com-
putes an aggregate score for all genes in the reference set,
based on their relative ranking in the data. Functional
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Analysis (IPA; Ingenuity Systems; http://www.ingenuity.
com) which enables the visualization and exploration of
molecular interaction networks on the basis of gene ex-
pression data. Networks were then algorithmically gener-
ated on the basis of their connectivity and were ranked by
IPA on the basis of the number of genes represented in
the network from the submitted gene list.In vivo xenograft analysis
This study was conducted at Proxy Bioresearch, Inc. at
its AAALAC accredited facility Proxy Bio, S.A. de C.V.
The study was conducted following industry standards
including compliance to United States Department of
Agriculture and NIH animal care and use guidelines.
Athymic nude mice were selected for this study because
they have been used for similar tumor grafting studies
and have been well-characterized. Daoy cell pellets were
prepared using standard harvest procedures, resus-
pended in PBS and 7 × 107 cells were injected with 50%
Matrigel by volume (BD Matrigel) using a 1 mL syringe
and 18 gauge 1/2 inch needle into the flank of each
mouse in an approximately 200 μL volume. Once tu-
mors were palpable and measurable (mean 52 days post
inoculation) treatment with MK-1775 or the control ve-
hicle of DMSO was begun.
Control or MK-1775 (30 mg/kg) was dosed for 3 con-
secutive days every 7 days for 3 weeks by oral gavage
and then followed for an additional 42 days with no
therapy given. Each animal was tracked individually for
tumor growth by external caliper measurements of sub-
cutaneous protruding tumor and an approximate tumor
volume was calculated using the ellipsoid volume for-
mula: π/6 × L × W × H. Animals were also weighed 3
times a week for the duration of the treatment. Upon
termination of the study the tumors were excised and
snap frozen in liquid nitrogen.Cell cycle analysis
Cells were treated with an IC30 of MK-1775, an IC25 of
cisplatin, or both for 24 hours. Cells were then har-
vested, washed with PBS and fixed in 70% ethanol.
Twenty-four hours after fixing cells were washed with
PBS and then resuspended in Guava Cell Cycle reagent
and analyzed on a Guava EasyCyte Plus flow cytometer.Statistics
The p value for the gene expression of the second large
cohort of 90 patient samples was calculated using the
Mann-Whitney U test. The remaining p values were cal-
culated using the Student’s t test. The error bars repre-
sent the standard error of the mean.Results
Cell cycle-related kinases are differentially expressed
in medulloblastoma
As a first step to identify novel molecular targets we per-
formed gene expression profiling on 16 medulloblastoma
samples and on corresponding normal cerebellar tissue.
The tumor samples were obtained at our institution at
the time of surgery and represent all major molecular
subgroups as previously described by us [24]. Gene ex-
pression was measured by Affymetrix microarrays [24].
We selected for dysregulated genes with a two-fold or
greater difference between medulloblastoma and normal
cerebellum (FDR 0.1). A total of 3683 transcripts were
differentially expressed in medulloblastoma. To identify
specific signaling networks we performed pathway ana-
lysis using IPA software (Ingenuity) and gene set enrich-
ment analysis. Cell cycle-related genes were the most
abundant in the molecular category and kinases were
the most abundant in the functional category. By com-
paring the molecular and functional categories with the
total dysregulated genes in medulloblastoma we found
50 specific genes that were common to all three categor-
ies (Figure 1A). The expression of these cell cycle-
related kinases is shown in the heat map in Figure 1B
and in Additional file 1: Table S1. Twenty-nine of the
fifty dysregulated cell cycle-related kinases are signifi-
cantly over expressed compared to normal cerebellum.
Role of protein and lipid kinases in medulloblastoma
cell proliferation
Based on our initial data that a subset of kinases are over
expressed in medulloblastoma we carried out a kinome-
wide siRNA screen to identify kinases that are essential
for medulloblastoma cell proliferation. The well charac-
terized Daoy cell line was chosen as we have significant
previous experience in manipulating it [24,25]. Daoy
cells were transfected with 2130 unique siRNAs target-
ing each of 710 kinase genes or a non-silencing control
in a 96 well format. Cell proliferation was evaluated by
the MTS assay (CellTiter AQueous) after 72 hours of
transfection. Absorbance values were normalized to ref-
erence controls on each plate to allow plate to plate
comparison and the average Z score was calculated
(Figure 1C). A Z score of < -2 was considered effective
on decreasing medulloblastoma proliferation. A total of
95 genes were identified that when inhibited decreased
Daoy cell growth (Figure 1C and Additional file 2: Table
S2). Fifty genes met our criteria when we use a more
stringent cutoff of Z < -3 with the 12 genes pertaining to
the lowest Z score shown in Figure 1D. Of these we have
previously reported on polo-like kinase 1 and aurora
kinase A [25,26]. We subsequently validated five of these
genes in an independent siRNA screen for their effect
on medulloblastoma cell proliferation (Additional file 3:
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in a biological phenotype due to the variability of siRNA
knockdown in cells.
Mitotic kinases are key determinants of medulloblastoma
cell growth
To integrate our gene expression data and our siRNA
screen we compared the two sets of data. The 29 genes
over expressed from the gene expression data was com-
pared to the 95 kinases identified to inhibit cell prolifera-
tion by the siRNA screen. Only 6 genes are over expressed
in medulloblastoma and also suppress medulloblastoma
cell growth. These are aurora kinase A, WEE1, TTK, aur-
ora kinase B, CDK2 and PLK1 (Figure 2A). Interestingly
all 6 genes are involved in the G2-M transition during the
cell cycle (Figure 2B). Our previous report on the import-
ance of aurora kinase A in medulloblastoma cell prolifera-
tion further validates this new methodology of identifying
genes by integrated genomic analysis [26,25]. We chose to
further examine the role of WEE1 kinase because it has
recently been reported to be involved in several tumors in-
cluding glioblastoma [27]. WEE1 regulates the G2-M cell
cycle checkpoint by preventing DNA damaged cells from
entering mitosis. We first examined the expression of
WEE1 in an independent cohort of 90 medulloblastoma
samples. Comparison of normal cerebellum with medul-
loblastoma showed significant over expression of WEE1
(p < 9.35E-7) in this disease. However there was no signifi-
cant difference in WEE1 expression between the recently
identified subgroups as shown in Figure 2C. Next WEE1
expression was examined in a panel of pediatric brain tu-
mors of differing pathological grade. WEE1 was over
expressed in all three high-grade tumors examined includ-
ing medulloblastoma (medullo), primitive neuroectoder-
mal tumor (PNET) and glioblastoma multiforme (GBM).
Interestingly WEE1 was also expressed in the low-grade
pilocytic astrocytoma (PA) in which there is very little pro-
liferation (Figure 2D). These data suggested that increased
WEE1 expression may be a key to tumorigenesis and not
simply a marker of proliferation. We next evaluated
WEE1 protein in two normal pediatric cerebellum sam-
ples, one adult normal cerebellum sample and in a panel
of well characterized medulloblastoma cell lines. WEE1
protein is not present in pediatric (UPN 514, 605) or adult
cerebellum but was present in varying amounts in the 6
medulloblastoma cell lines evaluated (Figure 2E).
Inhibition of WEE1 suppresses medulloblastoma cell
proliferation and colony forming potential in vitro
Daoy and UW228 cell lines were chosen to examine the
functional consequence of inhibiting WEE1. Using a
siRNA against WEE1 we measured cell proliferation using
the xCELLigence real-time cell analysis (RTCA) system.
Cell growth was monitored following transfection ofeither a non-silencing siRNA or one targeting WEE1. A
decrease in cell growth was seen in both the Daoy and
UW228 cell lines (Figure 3A). The more pronounced
decrease in growth seen in Daoy cells compared to
UW228 cells could be explained by the higher expres-
sion of WEE1 protein in Daoy cells compared to the
UW228 cell line (Figure 2E). We then chose to deter-
mine the ability of medulloblastoma cells to undergo
an unlimited number of divisions following inhibition
of WEE1 by performing a colony forming assay. The
siRNA targeting WEE1 showed a significant decrease
in the relative colony number when compared to the
non-silencing siRNA in both Daoy and UW228 cell
lines (Figure 3B). Western blots confirmed the specifi-
city and ability of the siRNA targeting WEE1 to de-
crease the WEE1 protein levels in Daoy and UW228
cells (Figure 3C).
Small molecule inhibitor of WEE1, MK-1775, potently sup-
presses medulloblastoma growth in vitro and in vivo
Recently several inhibitors of WEE1 have been described
[28-30]. We chose to examine MK-1775, a pyrazolo-
pyrimidine derivative, which has recently entered Phase
I/II trials in adult cancers. Daoy and UW228 cells were
exposed to various concentrations of MK-1775. The
IC50 values from the MTS assay were 150 nM and 232 nM
for Daoy and UW228 cell lines respectively (Figure 4A).
These nanomolar concentrations have been shown previ-
ously to be achievable in vivo and therefore make MK-1775
a clinically viable drug [31].
To evaluate the impact of MK-1775 on the long-term
proliferative capacity in medulloblastoma cells, colony
forming assays were performed in both Daoy and UW228
cell lines. In both cell lines 48 hour exposure to an IC30
of MK-1775 was sufficient to significantly decrease the
colony number counted after 1 week (p < 0.01, Figure 4B).
Furthermore, the Daoy cell line showed a significant de-
crease in relative colony number after exposure to an
IC15 of MK-1775 (p < 0.01). UW228 cells did not show a
further decrease in colony formation from the IC30 to
IC15, which likely reflects the heterogeneity of tumor
cells. Interestingly UW228 are p53 sufficient while Daoy
cells are not. Clearly the role of p53 status on MK-1775
activity in medulloblastoma needs to be further examined.
To assess whether MK-1775 was inhibiting WEE1 kinase
activity, we measured the phosphorylation status of its tar-
get CDK1 by immunoblotting. A decrease in phospho-
CDK1 (Tyr15) was seen in a dose-dependent manner with
MK-1775 treatment as shown in Figure 4C. There was no
significant change in WEE1 with MK-1775 treatment as
expected.
We next examined the efficacy of MK-1775 in treating
medulloblastoma tumors in vivo. Athymic nude mice were
injected with Daoy cells subcutaneously and palpable
Figure 3 siRNA-mediated inhibition ofWEE1 decreases medulloblastoma cell proliferation. (A) Daoy and UW228 cells transfected with a siRNA
targeting WEE1 (siWEE1) displayed a decrease in cell proliferation when compared to a non-silencing siRNA (siRNA N.C.). Forty-eight hours after transfection
cells were seeded into E-plates and real-time cell proliferation monitored using the xCELLigence system. (B) Transfection with siWEE1 significantly
decreased the relative colony number compared to siRNA N.C. Representative pictures for each treatment group are above the quantifying bar graphs.
(C) RNAi-mediated inhibition of WEE1 decreased the levels of WEE1 protein in both the Daoy and UW228 cell lines 72 hours after transfection.
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an oral gavage of either control solution or 30 mg/kg of
MK-1775 three times a week for three weeks (n = 10 each
group). MK-1775 was able to decrease the measurable size
of the tumors compared to controls as seen in Figure 4D
(p < 0.005). A decrease in tumor volume was observed on
day 63 at the termination of the study (Additional file 4:
Figure S2A, p < 0.01). Recent evidence suggests that inhib-
ition of WEE1 can lead to DNA damage. To determine if
the decrease in tumor volume may have resulted from in-
creased DNA damage snap frozen tumors were probed
for γH2AX, a marker of DNA double strand breaks. An
increase in γH2AX protein was seen in the MK-1775treated tumors when compared to the control tumors at
day 63 (Additional file 4: Figure S2B). There was no
change in the phosphorylation of CDK1, WEE1 or in the
total levels of CDK1 or WEE1 in the tumor samples (data
not shown) as expected. The tumors had only been
treated with MK-1775 during the initial part of the study
and we would not expect a transient marker like the phos-
phorylation of CDK1 to persist. These studies establish
the proof of principle that MK-1775 is a viable candidate
for medulloblastoma therapy. These data are further
supported by recent studies demonstrating the single
agent activity of MK-1775 in many different tumor cell
lines [32].
Figure 4 Inhibition of WEE1 by the small molecule inhibitor MK-1775. (A) A decrease in relative cell number was seen by MTS assay
through a wide range of MK-1775 concentrations in both Daoy and UW228 cells. From this data the IC50 values were calculated. (B) Treatment
with an IC30 of MK-1775 for 48 hours significantly decreased the relative colony numbers in Daoy and UW228 cells. Shown are representative
images from each treatment group with the quantifying bar graph for each cell line below the images. (C) Exposure to increasing concentrations
of MK-1775 in Daoy and UW228 cells showed a dose dependent decrease in WEE1 activity as seen by decreased phospho-CDK1 (Tyr15). There
was no significant change in WEE1 levels. (D) Treatment with MK-1775 is sufficient to decrease subcutaneous tumor growth of Daoy cells in mice.
Mice were treated on three consecutive days a week for the first three weeks after tumor establishment.
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Cisplatin forms the backbone of most medulloblastoma
chemotherapy protocols. Among the adverse effects of
cisplatin are cytotoxicity, nephrotoxicity and severe bonemarrow suppression. Thus drugs that can synergize with
cisplatin and facilitate a decrease in this chemotherapy
are of high value. We examined the ability of MK-1775
to synergize with cisplatin. Daoy cells were exposed to
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72 hours and the effect on cellular proliferation was
evaluated by MTS assay. The results were analyzed using
the Bliss Additivity model and show a synergistic rela-
tionship between cisplatin and MK-1775 at a concentra-
tion as low as 50 nM of MK-1775 (Figure 5A). The
effect of MK-1775 on the IC50 value for cisplatin was
also investigated using Daoy cells. Daoy cells have an
IC50 value of 593 nM for cisplatin alone by MTS assay.
Figure 5B shows a decrease in the IC50 value of cisplatin
down to 470 nM and 406 nM when Daoy cells were
treated with cisplatin and either 50 nM or 100 nM of
MK-1775 respectively.
MK-1775 induces caspase-mediated apoptosis in
medulloblastoma
To determine if the suppression of cellular growth was a
result of cell death, we evaluated the impact of MK-1775
on apoptosis in medulloblastoma cells. The Daoy cell
line was exposed to an IC30 of MK-1775, an IC25 of
cisplatin, or both for 48 hours. The cells were subse-
quently stained with Guava Nexin reagent for AnnexinFigure 5 MK-1775 acts synergistically with cisplatin. (A) Line graph de
of MK-1775 on Daoy relative cell number by MTS assay. The black line repr
calculated effect of cisplatin and 50 nM MK-1775 using the Bliss Additivity
50 nM MK-1775 combination treatments. (B) The bar graph depicts the cal
to cisplatin (0 nM MK-1775) or in combination with 50 nM MK-1775 or 100
on apoptosis resulting from 48 hours of drug treatment in Daoy cells follow
right quadrants show cells that are Annexin V positive and thus considered
percent of cells apoptotic or dead in these two quadrants for the replicate
MK-1775 increased the percentage of apoptotic cells. **p < 0.01; ***p < 0.00V expression and analyzed using a flow cytometer.
Treatment with MK-1775 alone for 48 hours caused an
increase in apoptotic cells (Figure 5C). Moreover, a sig-
nificant increase in the percentage of Annexin V posi-
tive cells was seen when cells were treated with both
MK-1775 and cisplatin compared to treatment with ei-
ther drug alone (p < 0.01). The increase in apoptotic
cells can also be seen by increased caspase 3 staining in
the immunofluorescence images in Additional file 5:
Figure S3.
MK-1775 treatment produces DNA damage and inhibits
repair of cisplatin-induced DNA damage
The DNA damage pathway plays an important part for
the survival of tumor cells, especially after treatment with
DNA damaging agents. To examine the impact of MK-
1775 on medulloblastoma cells, we analyzed for DNA
damage by staining with an antibody against γH2AX and
co-staining of the nuclei with DAPI (Figure 6A). γH2AX
is recruited to sites of damaged DNA and is removed once
DNA is repaired. After 6 hours of treatment with an IC30
of MK-1775 and/or an IC25 of cisplatin both significantlypicting the effect of different cisplatin doses with or without treatment
esents cells treated only with cisplatin. The blue line depicts the
model. The red line represents the observed effect of cisplatin and
culated IC50 value by MTS assay of cisplatin in Daoy cells exposed only
nM MK-1775. (C) Representative flow cytometry plots depict the effect
ing staining with Guava Nexin reagent. The lower right and upper
apoptotic or dead. The bar graph on the right quantifies the average
samples. The combination of an IC25 of cisplatin with an IC30 of
1.
Figure 6 Cisplatin-induced DNA damage is increased with MK-1775 treatment. (A) Immunofluorescence images of Daoy cells treated with
an IC30 of MK-1775 or an IC25 of cisplatin or both drugs for the time periods as indicated. Cells were stained with DAPI (blue) for total DNA
content and with an antibody against γH2AX (green) to visualize DNA damage. (B) Quantifying bar graph showing the normalized percentage of
γH2AX positive Daoy cells co-stained with DAPI nuclear cells.
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http://www.molecular-cancer.com/content/13/1/72induced DNA damage as measured by γH2AX foci in
Daoy cells (Figure 6A). However there was no significant
difference between the percentages of γH2AX positive
cells in cisplatin alone or MK-1775 treated cells for 6 hours
(Figure 6B). We then measured existing DNA damage
after treatment with cisplatin, MK-1775 or both for
24 hours. While there was a decrease in γH2AX foci in
cisplatin alone treated cells compared to 6 hour treatment,
there was an increase in γH2AX foci in cells treated with
both MK-1775 and cisplatin. These data indicate that add-
ing MK-1775 inhibits DNA damage repair seen after
24 hours of treatment with cisplatin alone.Discussion
Medulloblastoma is a clinically and genomically heteroge-
neous disease. This heterogeneity creates a major challenge
in developing novel therapy and improving outcomes in
medulloblastoma using traditional approaches. Thus, novel
approaches that more rapidly identify and validate media-
tors of cell survival have the potential to dramatically alter
our understanding of cellular biology and develop novel
therapeutic strategies. We hypothesized that escape path-
ways on which medulloblastoma cells are dependent for
survival would represent ideal targets for therapy. To
identify these pathways we integrated descriptive and
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for rationale therapy development. We identified a me-
dulloblastoma specific kinase expression profile that can
provide insight into future kinase inhibition therapeutic
strategies. Next using RNAi functional genomics target-
ing the kinome we identified key molecules that mediate
medulloblastoma cell proliferation. Integration of these
data suggests that the mitotic cell cycle checkpoint is a
critical determinant of medulloblastoma tumorigenesis.
In particular we identified WEE1 as a potential thera-
peutic target. A combination of in vitro and in vivo
studies clearly indicates that WEE1 mediates medullo-
blastoma tumorigencity and represents a novel thera-
peutic target. These data demonstrate the power of
integrating descriptive and functional genomics to iden-
tify novel therapeutic targets. Using a similar kinome-
wide RNAi screen Guerreiro et al., previously identified
PI3K p110γ as a molecule that demonstrated synthetic
lethality with cisplatin in medulloblastoma [33]. To-
gether with our data these two studies demonstrate the
utility of functional genomics to identify novel thera-
peutic targets in medulloblastoma.
Cell cycle checkpoint genes have previously been im-
plicated in medulloblastoma [34-36]. However to our
knowledge this is the first report in medulloblastoma to
document the functional importance of mitotic kinases
and in particular WEE1. WEE1 controls the G2-M tran-
sition by catalyzing the inhibitory phosphorylation of
CDK1 thus preventing the Cyclin B-CDK1 complex
from driving cells into mitosis [37]. The G2-M cell cycle
checkpoint is critical for eukaryotic organisms ensuring
cells do not initiate mitosis before DNA damage is
repaired [38]. WEE1 is a key regulator of this process
[37,28]. Thus abrogation of the G2-M checkpoint lead-
ing to premature mitotic entry and subsequent cell death
by mitotic catastrophe has emerged as a promising new
therapeutic strategy [39,38].
WEE1 over expression is associated with several types
of cancer [38]. More recently an in silico analysis of a
large data set of glioblastoma identified WEE1 as over
expressed and a key regulator of mitotic catastrophe
[27]. Similarly a functional genomic approach in acute
myeloid leukemia also identified WEE1 as a key regula-
tor of chemotherapy sensitivity [40]. This study shows
that WEE1 is over expressed and functionally important
in medulloblastoma. Our data show that the small mol-
ecule inhibitor of WEE1, MK-1775, is a potent inhibitor
of medulloblastoma cell growth and synergizes with cis-
platin to decrease cell proliferation in vitro. Cisplatin in
combination with MK-1775 treatment induces an in-
crease in the percentage of cells in the S and G2-M
phases of the cell cycle (Additional file 6: Figure S4A)
and subsequently leads to more DNA damage as mea-
sured by γH2AX foci than DNA damage induced bycisplatin alone. Similarly an increase in mitosis was dem-
onstrated in the combination treatment by increased
phospho-H3 staining as seen in Additional file 6: Figure
S4B and C. Interestingly, MK-1775 as a single agent po-
tently inhibits medulloblastoma tumor growth in vivo.
These data could be explained by the fact that MK-1775
induces DNA damage and genomic instability. MK-1775
has recently been shown to inhibit growth of sarcoma
cells and glioblastoma cells among many other tumor
types [31,41,42].
Inhibition of WEE1 has largely been investigated in
the context of abnormal p53 function, given that cells
with impaired p53 function are highly dependent on the
G2-M checkpoint to maintain genomic integrity [43].
For example studies have demonstrated that cells with
dysfunctional p53 can be sensitized to DNA damage by
impairing the G2-M checkpoint through inhibition of
WEE1 [30]. Our data showing synergy of WEE1 inhib-
ition in combination with cisplatin were generated in a
medulloblastoma cell line that has nonfunctional p53. A
more thorough investigation with additional functional
p53, nonfunctional p53 and isogenic cell lines are
needed to determine the role of p53 on the effectiveness
of WEE1 inhibition to sensitize cells to DNA damaging
agents.
We have demonstrated that WEE1 inhibition sensi-
tizes medulloblastoma cells to cisplatin in vitro. However
it is unlikely that all patients with medulloblastoma will
respond in a similar manner. Thus, it will be important
to develop suitable biomarkers to predict which patients
may benefit the most from such a therapeutic strategy.
Detailed animal modeling of medulloblastoma with assess-
ment of potential biomarkers as well as pharmacokinetics
will provide further data in evaluating the effectiveness of
WEE1 inhibition in conjunction with cisplatin in eradicat-
ing medulloblastoma cells in vivo and prolonging patient
survival.
Importantly, MK-1775 is a well-tolerated drug with low
dose limiting toxicities [44]. Clinical trials are now under-
way for MK-1775 including combination with carboplatin
for ovarian cancer (NCT01164995) and combination with
gemcitabine, cisplatin or carboplatin in advanced solid
tumors (NCT00648648). Because MK-1775 crosses the
blood brain barrier it is a promising agent for brain tumor
therapy. In fact a Phase I trial in glioblastoma multiforme
in adults is currently underway (NCT01849146) as well as
a newly initiated trial for diffuse intrinsic pontine glioma
in children (NCT01922076). For medulloblastoma therapy
we envision a strategy of administering MK-1775 thrice
weekly for 3 weeks with each cycle of cisplatin. Thus once
the maximum tolerated dose is obtained in a Phase I trial,
we would propose a Phase II/III trial of cisplatin based
therapy (the current standard of care) compared to cis-
platin plus MK-1775.
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http://www.molecular-cancer.com/content/13/1/72In summary our data supports a role for WEE1 in
regulating the G2-M checkpoint in medulloblastoma
and validated WEE1 as a therapeutic target. We demon-
strate that a clinically relevant small molecule inhibitor,
MK-1775, is potent in the inhibition of medulloblastoma
tumor growth in vivo. In light of our data and that of
others, in combination with the good positive safety pro-
file, we suggest that MK-1775 is an exciting new agent
in the treatment of pediatric brain tumors, particularly
medulloblastoma.
Additional files
Additional file 1: Table S1. Dysregulated cell cycle-related kinases in
medulloblastoma.
Additional file 2: Table S2. Genes that attenuate medulloblastoma
cell growth.
Additional file 3: Figure S1. Inhibition of cell cycle-related kinases
decreased Daoy cell proliferation. Shown are five select kinases
demonstrating a decrease in medulloblastoma proliferation by MTS
assay. The bar graphs show the effect of the three separate siRNAs from
the kinase screen on relative cell number after being normalized to the
non-silencing control siRNA (siRNA N.C.). ***p < 0.001.
Additional file 4: Figure S2. MK-1775 treatment decreases tumor
volume and increases DNA damage in Daoy xenografts. (A) The graph
depicts the average subcutaneous tumor volume in mice treated with
the vehicle control DMSO or MK-1775 at the termination of the study. (B)
Western blot analysis of tumors isolated at the termination of the study
demonstrates an increase in γH2AX protein for mice treated with MK-
1775 when compared to control.
Additional file 5: Figure S3. MK-1775 induces caspase 3 activation in
medulloblastoma cells. Immunofluorescence images of Daoy cells treated
with an IC30 of MK-1775 or an IC25 of cisplatin or both drugs are shown.
Total DNA content is visualized by blue DAPI staining and caspase 3 is
shown by green staining.
Additional file 6: Figure S4. Combination treatment with MK-1775 and
cisplatin increases mitosis in Daoy cells. (A) Cell cycle analysis of Daoy
cells treated with an IC30 of MK-1775, an IC25 of cisplatin or both for
24 hours. An increase in the percentage of cells in S and G2-M phases
was observed with combination treatment. (B) Representative
immunofluorescence images of Daoy cells treated with an IC30 of
MK-1775, an IC25 of cisplatin, or both for 24 hours. Blue DAPI staining
demonstrates nucleated cells and green staining depicts phospho-H3. (C)
Quantitation of phospho-H3 positive cells in each treatment group
normalized to DAPI.
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